DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for anaplastic large cell lymphoma — screening already-approved drugs against its 43-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAnaplastic large cell lymphoma maps to a 43-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for anaplastic large cell lymphoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
clathrin heavy chain (CLTC) — CLTC is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 4-nitrophenyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6E4L · 1.6 Å · ligand 5-bromo-N-(4-nitrophenyl)thiophene-2-sulfonamide (HRS). Experimental structure, not a prediction.
What the evidence adds up to
A 2007 case report describes one child with anaplastic large cell lymphoma that had relapsed after stem cell transplantation and was treated with pretargeted antibody-guided radioimmunotherapy. The child achieved a complete remission and maintained excellent quality of life for the ten months of follow-up reported. The abstract notes that up to 80% of paediatric ALCL patients are cured with multi-agent chemotherapy, but those with resistant disease or early relapse have a poor prognosis and poor chance of survival. No other patients were treated in this report, and no survival or response rates beyond this single case are given.
A 2011 review of primary cutaneous anaplastic large-cell lymphoma states that this subtype has a 95% disease-specific five-year survival, attributed partly to a relatively benign course and partly to the availability of effective treatments. The same review notes that new drugs are continually being tested, with immunotherapy and biological response modifiers described as showing promise, but provides no concrete numbers from any specific trial.
A separate 2011 review of ALCL pathogenesis states that the disease is a distinct subset of T-cell non-Hodgkin's lymphoma with low incidence, and that general pathogenic understanding is lacking. It summarises epidemiology, clinical manifestations, and treatment but offers no new trial data or quantitative outcomes.
What is still missing is any controlled trial of radioimmunotherapy in ALCL beyond a single paediatric case, any randomised comparison of pretargeted antibody-guided radioimmunotherapy against standard salvage regimens, and any prospective data on patient stratification by CD30 expression level or ALK status in the context of this approach. Funding for a multi-centre trial and a defined protocol for patient selection remain absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
European Journal Of Haematology · 2007 · 10 citations
Pretargeted antibody‐guided radioimmunotherapy in a child affected by resistant anaplastic large cell lymphoma
AbstractAnaplastic large cell lymphoma (ALCL) is characterized by preferential paracortical and intrasinusoidal lymph node involvement by large anaplastic tumor cells expressing the CD30 antigen. Up to 80% of pediatric patients with ALCL can be cured with multi-agent chemotherapeutic regimens. Patients resistant to chemotherapy or suffering from early relapse have a poor prognosis and a poor chance of survival. In these cases, the highly aggressive clinical course of ALCL, associated with systemic symptoms and extranodal involvement, has been treated with different approaches in various cooperative trials, including conventional chemotherapy and human stem cell transplantation (HSCT). However, the optimal treatment has not yet been defined, in particular in cases of relapse. More recently, radioimmunotherapy has been studied with encouraging results in cancer patients, including non-Hodgkin's lymphoma. Here we describe the case of a pediatric ALCL, relapsing after HSCT, treated with pretargeted antibody-guided radioimmunotherapy, obtaining a complete remission, with excellent quality of life over the past 10 months.
American Journal of Clinical Oncology · 2011 · 9 citations
Primary Cutaneous Anaplastic Large-cell Lymphoma
AbstractSince the recognition of the anaplastic large-cell lymphomas in the 1980s, much has been learned about the diagnosis, clinical presentation, and treatment of these malignant conditions. The systemic and primary cutaneous types of anaplastic large cell lymphomas have been differentiated on clinical and immunophenotypical findings, but further research is required to elucidate their exact etiologies and pathogeneses. Primary cutaneous anaplastic large-cell lymphoma has a 95% disease-specific 5-year survival, owing partly to the relatively benign course of the disease and partly to the variety of effective treatments that are available. As with many other oncological diseases, new drugs are continually being tested and developed, with immunotherapy and biological response modifiers showing promise.
Research progresses in the pathogenesis of anaplastic large cell lymphoma
AbstractAnaplastic large cell lymphoma (ALCL) is a distinct subset of T-cell non-Hodgkin's lymphoma. As a consequence of its low incidence, general pathogenic consideration of ALCL is lacking. In this review, we summarize the pathogenesis, epidemiology, clinical manifestations, and treatment of ALCL, so as to better understand key stages of the development of this disease and provide valuable information for future treatment.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
